Need to Prevent Unwanted Abortions
When contraception is affordable, abortion should rarely be necessary. The abortion rate is now at an all-time low in the developed countries- it dropped by more than 40 % over the past 25 years. This is because many anti-abortion groups have grown louder in many European countries, in the recent years. In the United States, the teen pregnancy rate is substantially higher than in other western industrialized nations. According to a report published in 2016, there were 62 million American women in their childbearing years (15-44). About 43 million of them (70%) were at risk of unintended pregnancy, i.e., they were sexually active and do not want to get pregnant; however, they could become pregnant if they fail to use a contraceptive method correctly and consistently. Center for Disease Control and Prevention (CDC) identified the need to curb this growth of unwanted pregnancies, and has taken up initiatives to educate and prevent unwanted abortions and pregnancies- emphasis on the usage of contraceptive pills, is one such initiative. So, the rate of abortion is drastically reducing and the usage of contraceptives such as oral contraceptives usage is increasing. The other factors, like the government and NGO initiatives to promote contraception and the emphasis on family planning, are driving the market.
Side Effects Associated with the Use of Contraceptive Drugs and Devices
Nowadays, a woman has a lot of choices, when compared to the olden days, for wanting to ward off pregnancy. Various methods of contraception include, pills, injection, and vaginal rings comprising of synthetic hormones. Every method is filed with its benefits and side effects. For example, oral contraceptive pills is a well-known method, utilized for avoiding unwanted pregnancy or for family planning. The birth control pill is estimated to be used by around 100 million women, across the world. Like most medications, birth control pills too have side effects. In the same way, a few complications are associated with the use of contraceptive devices like Intrauterine Devices (IUD). There have been cases where a copper IUD was responsible for increased menstrual bleeding and cramps. Spotting between periods has been observed in women using copper IUDs. Such side effects, associated with contraceptive methods, are hindering the growth of the female contraceptive market. The rising prevalence of infertility among women and cultural or religious opposition, are restraining the market growth of the female contraceptives.
The United States has the Highest Market Share
In North America, the United States is dominating the female contraceptives market, due to the maximum percentage of the female population in North America that uses the modern contraceptives techniques. Asia-Pacific is expected to record a substantial growth over the forecast period, due to the increasing awareness among people and several government initiatives.
Key Developments in the Market
- October 2017: Lupin acquired Symbiomix Therapeutics LLC.
- June 2017: Johnson & Johnson acquired Actelion.
Reasons to Purchase the Report
- Current and future market outlook for female contraceptives, in the developed and emerging markets
- Analyze various perspectives of the market, with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth, during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3-month analyst support, along with the market estimate sheet (in excel)
This report can be customized to meet your requirements.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Need to Prevent Unwanted Abortions
6.1.2 Government and NGO Initiatives to Promote Contraception
6.1.3 Immediate Health Benefits Other than Birth Control
6.1.4 Emphasis on Family Planning
6.2 Market Restraints
6.2.1 Rising Prevalence of Infertility among Women
6.2.2 Cultural or Religious Opposition
6.2.3 Side Effects Associated with the Use of Contraceptive Drugs and Devices
6.4 Key Challenges
7. Market Segmentation
7.1 Segmentation -by Contraceptive Drugs
7.1.1 Contraceptive Pills
184.108.40.206 Hormonal Pills
220.127.116.11.1 Combined Oral Contraceptive Pill
18.104.22.168.2 Progestin Only Pill
22.214.171.124 Non-Hormonal Pill
7.1.2 Contraceptive Injections
7.1.3 Topical Contraceptives
7.2 Segmentation -by Contraceptive Devices
7.2.1 Female Condoms
7.2.2 Diaphragms and Caps
7.2.3 Vaginal Rings
7.2.4 Contraceptive Sponges
7.2.5 Sub-dermal Contraceptive Implants
7.2.6 Intra Uterine Contraceptive Devices (IUCDs)
126.96.36.199 Copper IUCDs
188.8.131.52 Hormonal IUCDs
7.2.7 Contraceptive Patches
7.3 Segmentation - by Geography
7.3.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 New Zealand
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
7.3.4 Middle East & Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle East & Africa
7.3.5 South America
18.104.22.168 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 Bayer HealthCare AG
9.2 Mayer Laboratories Inc.
9.3 Pfizer Inc.
9.4 Mylan Pharmaceuticals Inc.
9.5 Teva Women's Health Inc.
9.6 Merck & Co.
9.7 Johnson & Johnson Ltd
9.8 Lupin Pharmaceuticals Ltd
9.9 The Female Health Company
9.10 Fuji Latex Co. Ltd
10. Future of the Market
- BAYER HEALTHCARE AG
- MAYER LABORATORIES INC.
- PFIZER INC.
- MYLAN PHARMACEUTICALS INC.
- TEVA WOMEN'S HEALTH INC.
- MERCK & CO.
- JOHNSON & JOHNSON LTD
- LUPIN PHARMACEUTICALS LTD
- THE FEMALE HEALTH COMPANY
- FUJI LATEX CO. LTD.